KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Assets (2016 - 2025)

TherapeuticsMD's Non-Current Assets history spans 16 years, with the latest figure at $23.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 12.62% year-over-year to $23.2 million; the TTM value through Dec 2025 reached $98.1 million, down 13.01%, while the annual FY2025 figure was $23.2 million, 12.62% down from the prior year.
  • Non-Current Assets reached $23.2 million in Q4 2025 per TXMD's latest filing, down from $24.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $52.3 million in Q1 2021 to a low of $23.2 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $36.3 million, with a median of $33.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: fell 6.02% in 2021, then fell 29.79% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $50.0 million in 2021, then fell by 29.79% to $35.1 million in 2022, then dropped by 10.24% to $31.5 million in 2023, then decreased by 15.71% to $26.6 million in 2024, then fell by 12.62% to $23.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Non-Current Assets are $23.2 million (Q4 2025), $24.2 million (Q3 2025), and $25.0 million (Q2 2025).